TEPOTINIB TAB
Clinical Criteria Summary
Exclusion Criteria
- CrCl <30 mL/min
- Prior treatment with another MET inhibitor
- Severe Hepatic Insufficiency: (Child Pugh C or NCI Organ Dysfunction Working Group classification unless with Gilbert syndrome)
- Inadequate hematologic function: Hgb <8.5 g/dL or Neutrophils <1.5/mm3 (unless Duffy null phenotype) or Plt <100/mm3
- Presence of ALK mutation or sensitive EGFR mutation (exon 19 del or exon 21 alteration)
- NYHA heart failure Class III or IV
- Untreated brain metastases
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Lactating
Inclusion Criteria
- Patients with metastatic non-small cell lung cancer with a MET exon 14 skipping mutation
Additional Inclusion Criteria
- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented
- Patients of child-bearing potential and patients with partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for one week after the last dose.